Table 1.
Baseline characteristics of the study population.
| Baseline Characteristics | Global Study Population (N = 84) |
|
|---|---|---|
| Age—years | 65.52 ± 10.87 | |
| Gender (female)—no. (%) | 14 (17) | |
| Hypertension—no. (%) | 59 (83) * | |
| Dyslipidemia—no. (%) | 55 (89) * | |
| Diabetes mellitus—no. (%) | 28 (78) * | |
| Smoking—no. (%) | 42 (50) | |
| Chronic kidney disease—no. (%) | 11 (29) * | |
| Creatinine (mg/dL) | 0.89 (0.76–1.12) | |
| Dyalisis—no. (%) | 1 (4) * | |
| Prior MI—no. (%) | 19 (50) * | |
| LVEF (%) | 57 (46–60) | |
| Peak Troponin (ui/mL) | 805 (135–4000) | |
| Prior PCI—no. (%) | 31 (65) * | |
| Peripheral artery disease—no. (%) | 4 (14) * | |
| Clinical presentation—no. (%) | ||
| Stable angina | 32 (38) | |
| Unstable angina | 11 (13) | |
| Non-ST-elevated MI | 33 (39) | |
| LVEF deterioration | 8 (10) | |
| Medications | ||
| Aspirin | 81 (96) * | |
| Ticagrelor | 28 (33) * | |
| Clopidogrel | 47 (56) * | |
| Prasugrel | 7 (8) * | |
| Direct oral anticoag. | 7 (8) * | |
| Warfarine | 1 (1) * | |
| Killip Kimball | ||
| I–II | 46 (92) * | |
| III–IV | 4 (8) *^ | |
| CCS class | ||
| I | 9 (36) * | |
| II | 14 (56) * | |
| III | 2 (8) * | |
Values are expressed as means ± standard deviation (SD), medians (interquartile ranges), or n (cumulative %, * valid %). ^ among the Killip III–IV patients, all patients had a Killip III class.